We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Should Stay Neutral on Cigna Stock for Now
Read MoreHide Full Article
Key Takeaways
Cigna benefits from strong Specialty and Care Services and employer business growth.
Cigna's pharmacy strategy, AI initiatives and buybacks support its growth and shareholder value.
Rising expenses, a higher medical cost ratio and significant debt pose risks to margin growth.
The Cigna Group (CI - Free Report) continues to drive growth on the back of strong segmental performance, improving operating efficiency and shareholder-friendly moves. Its forward P/E of 8.61X is lower than the industry average of 16X.
Cigna — with a market capitalization of $73.6 billion — offers a variety of health solutions and insurance products. It operates through two main divisions: Cigna Healthcare and Evernorth Health Services. The company’s shares have gained 1.2% in the year-to-date period compared with the industry average of a 20.3% rise.
Courtesy of solid prospects, Cigna currently carries a Zacks Rank #3 (Hold) and Value Score of A.
Where Do Estimates for CI Stand?
The Zacks Consensus Estimate for Cigna’s 2026 earnings is pegged at $30.50 per share, indicating a 2.2% year-over-year rise. In the past month, it has witnessed eight upward estimate revisions against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $288.8 billion for 2026.
It beat earnings estimates in each of the past four quarters, with the average surprise being 2.3%.
Cigna is benefiting from strong growth in its Specialty and Care Services business, supported by rising specialty-drug utilization and faster adoption of biosimilars and specialty generics. Evernorth’s Specialty and Care Services delivered 22% year-over-year growth in pretax adjusted earnings to $1.1 billion in the second quarter of 2026. Higher generic penetration, operating efficiencies and contributions from Shields Health Solutions, which expands Cigna’s reach across hospitals and health systems, also supported the performance. In the second quarter of 2026, Evernorth Health Services’ adjusted revenues increased 6.3% year over year.
Cigna Healthcare is another key growth driver, with the U.S. employer business benefiting from strong client relationships, disciplined pricing and effective care coordination. Second-quarter adjusted revenues increased 9.1% year over year to $11.7 billion, while pretax adjusted earnings rose 17%, supported by favorable medical cost trends and continued membership growth in the employer market.
CI is also reshaping its pharmacy benefits business to create a more sustainable growth platform. Its new Signature rebate-free pharmacy model has generated early interest from health plans and employers and is expected to be introduced to Cigna Healthcare’s fully insured plans next year before a broader market launch in 2028. Pharmacy Benefit Services also achieved more than 97% client retention for 2026, while new business secured for 2027 already exceeds the combined level of the previous two selling seasons.
Technology and AI are emerging as additional levers for improving care, affordability and efficiency. Cigna’s Pharmacy Forward program is expected to halve the average time to therapy for specialty medications and reduce clinician documentation time by up to 50%. Meanwhile, expanded AI-enabled care coordination is expected to reach 20% more customers with emerging complex health needs. Customers participating in these programs have seen approximately $2,000 in annual medical-cost savings and a 42% reduction in avoidable inpatient stays.
Cigna continues to demonstrate a strong commitment to enhancing shareholder value. During the second quarter of 2026, it repurchased approximately 0.9 million shares for about $250 million. Its current dividend yield of 2.24% is higher than the industry average of 2.02%.
CI: Risks to Watch
However, there are some factors that investors should keep a careful eye on.
The company’s total benefits and expenses escalated over the last several years due to higher pharmacy and other service costs, medical costs and other benefit expenses. Total benefits and expenses witnessed a year-over-year increase of 6% in the second quarter of 2026. The persistent escalation of expenses might weigh on its margin growth. In the second quarter of 2026, the medical cost ratio deteriorated 130 bps year over year to 84.5%.
Cigna has been grappling with a significant debt level over the past several years. As of June 30, 2026, it had a long-term debt of $29.1 billion, significantly higher than the cash balance of $6.3 billion. This is likely to put pressure on the company’s interest expenses. Its net debt to capital is 32.9%, higher than the industry’s average of 18.4%.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.78 per share has witnessed five upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.2 billion, suggesting 18.1% year-over-year growth.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.93 per share has witnessed three upward revisions in the past 30 days, against no movement in the opposite direction. GMED Pharmaceuticals beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Investors Should Stay Neutral on Cigna Stock for Now
Key Takeaways
The Cigna Group (CI - Free Report) continues to drive growth on the back of strong segmental performance, improving operating efficiency and shareholder-friendly moves. Its forward P/E of 8.61X is lower than the industry average of 16X.
Cigna — with a market capitalization of $73.6 billion — offers a variety of health solutions and insurance products. It operates through two main divisions: Cigna Healthcare and Evernorth Health Services. The company’s shares have gained 1.2% in the year-to-date period compared with the industry average of a 20.3% rise.
Courtesy of solid prospects, Cigna currently carries a Zacks Rank #3 (Hold) and Value Score of A.
Where Do Estimates for CI Stand?
The Zacks Consensus Estimate for Cigna’s 2026 earnings is pegged at $30.50 per share, indicating a 2.2% year-over-year rise. In the past month, it has witnessed eight upward estimate revisions against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $288.8 billion for 2026.
It beat earnings estimates in each of the past four quarters, with the average surprise being 2.3%.
Cigna Group Price, Consensus and EPS Surprise
Cigna Group price-consensus-eps-surprise-chart | Cigna Group Quote
CI’s Growth Drivers
Cigna is benefiting from strong growth in its Specialty and Care Services business, supported by rising specialty-drug utilization and faster adoption of biosimilars and specialty generics. Evernorth’s Specialty and Care Services delivered 22% year-over-year growth in pretax adjusted earnings to $1.1 billion in the second quarter of 2026. Higher generic penetration, operating efficiencies and contributions from Shields Health Solutions, which expands Cigna’s reach across hospitals and health systems, also supported the performance. In the second quarter of 2026, Evernorth Health Services’ adjusted revenues increased 6.3% year over year.
Cigna Healthcare is another key growth driver, with the U.S. employer business benefiting from strong client relationships, disciplined pricing and effective care coordination. Second-quarter adjusted revenues increased 9.1% year over year to $11.7 billion, while pretax adjusted earnings rose 17%, supported by favorable medical cost trends and continued membership growth in the employer market.
CI is also reshaping its pharmacy benefits business to create a more sustainable growth platform. Its new Signature rebate-free pharmacy model has generated early interest from health plans and employers and is expected to be introduced to Cigna Healthcare’s fully insured plans next year before a broader market launch in 2028. Pharmacy Benefit Services also achieved more than 97% client retention for 2026, while new business secured for 2027 already exceeds the combined level of the previous two selling seasons.
Technology and AI are emerging as additional levers for improving care, affordability and efficiency. Cigna’s Pharmacy Forward program is expected to halve the average time to therapy for specialty medications and reduce clinician documentation time by up to 50%. Meanwhile, expanded AI-enabled care coordination is expected to reach 20% more customers with emerging complex health needs. Customers participating in these programs have seen approximately $2,000 in annual medical-cost savings and a 42% reduction in avoidable inpatient stays.
Cigna continues to demonstrate a strong commitment to enhancing shareholder value. During the second quarter of 2026, it repurchased approximately 0.9 million shares for about $250 million. Its current dividend yield of 2.24% is higher than the industry average of 2.02%.
CI: Risks to Watch
However, there are some factors that investors should keep a careful eye on.
The company’s total benefits and expenses escalated over the last several years due to higher pharmacy and other service costs, medical costs and other benefit expenses. Total benefits and expenses witnessed a year-over-year increase of 6% in the second quarter of 2026. The persistent escalation of expenses might weigh on its margin growth. In the second quarter of 2026, the medical cost ratio deteriorated 130 bps year over year to 84.5%.
Cigna has been grappling with a significant debt level over the past several years. As of June 30, 2026, it had a long-term debt of $29.1 billion, significantly higher than the cash balance of $6.3 billion. This is likely to put pressure on the company’s interest expenses. Its net debt to capital is 32.9%, higher than the industry’s average of 18.4%.
Stocks to Consider
Some better-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Globus Medical, Inc. (GMED - Free Report) and Centene Corporation (CNC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.78 per share has witnessed five upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.2 billion, suggesting 18.1% year-over-year growth.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.93 per share has witnessed three upward revisions in the past 30 days, against no movement in the opposite direction. GMED Pharmaceuticals beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.